A multi-centre, double-blind, randomised, placebo-controlled crossover study of tiotropium treatment in adult patients with stable, non-cystic fibrosis bronchiectasis.
Latest Information Update: 29 Nov 2021
Price :
$35 *
At a glance
- Drugs Tiotropium bromide (Primary)
- Indications Bronchiectasis
- Focus Therapeutic Use
- Acronyms ROBUST
- 18 Nov 2021 Primary endpoint (Event-based exacerbation frequency- ascertained using data from the daily diary card kept by participants and clinical assessment during follow up visits.) has not been met according to the results published in the European Respiratory Journal
- 18 Nov 2021 Results published in the European Respiratory Journal
- 27 Jul 2016 Status changed from recruiting to completed.